创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Introduction to the Features of iHuPBMC-B

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-29 13:52
  • Views:

(Summary description)In the field of life sciences, InnoModels Biotechnology is leading the industry with its outstanding innovation and cutting-edge technologies. Among them, iHuPBMC-B is a high-profile product of InnoModels Biotechnology, which has revolutionized scientific research with its unique features and advantages

InnoModels: Introduction to the Features of iHuPBMC-B

(Summary description)In the field of life sciences, InnoModels Biotechnology is leading the industry with its outstanding innovation and cutting-edge technologies. Among them, iHuPBMC-B is a high-profile product of InnoModels Biotechnology, which has revolutionized scientific research with its unique features and advantages

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-02-29 13:52
  • Views:
Information

In the field of life sciences, InnoModels Biotechnology is leading the industry with its outstanding innovation and cutting-edge technologies. Among them, iHuPBMC-B is a high-profile product of InnoModels Biotechnology, which has revolutionized scientific research with its unique features and advantages.
First of all, iHuPBMC-B is highly analog. It mimics the physiological environment of human peripheral blood single nucleated cells (PBMCs), providing a powerful tool for studying the behavior of PBMCs under various physiological and pathological conditions. This enables scientists to conduct in-depth studies in an in vitro environment that mimics the real situation in the human body.
Secondly, iHuPBMC-B is extremely reproducible. Due to its strict standardized production process, the results of each experiment are highly consistent and reproducible. This greatly improves the accuracy and reliability of scientific research and provides researchers with strong data support.

 


Furthermore, iHuPBMC-B has a wide range of applications. Whether it is drug screening, immunology research, or disease model construction, iHuPBMC-B can play its unique role. Its wide range of applications enables researchers to conduct various experiments more flexibly and promote the progress of scientific research.
In addition, iHuPBMC-B is easy and fast to use. It does not require complicated operating steps, and reliable experimental results can be obtained by simply following the instructions in the manual. This greatly reduces the difficulty of experiments and enables more researchers to utilize this tool for in-depth studies.
Finally, iHuPBMC-B has a good price/performance ratio. Although it adopts the most advanced technology and strict production process, its price is relatively affordable. This makes it affordable for more research institutions and laboratories, thus allowing more researchers to enjoy the convenience of this tool.
To sum up, iHuPBMC-B from InnoModels Biotechnology has revolutionized scientific research with its features and advantages such as high simulation, reproducibility, application range, ease of use, and good cost performance. It is believed that in the future, iHuPBMC-B will continue to play its important role in promoting the development of life science field.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司